Syra Health Q3 EPS $(0.06) Beats $(0.21) Estimate, Sales $2.25M Beat $1.99M Estimate
Portfolio Pulse from Benzinga Newsdesk
Syra Health reported better-than-expected Q3 results with EPS of $(0.06) beating the $(0.21) estimate and sales of $2.25M surpassing the $1.99M estimate. This marks a significant improvement from the previous year.
October 29, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Syra Health's Q3 earnings report shows a significant improvement with EPS and sales beating analyst estimates. The EPS of $(0.06) is a 71.43% beat over the $(0.21) estimate, and sales of $2.25M beat the $1.99M estimate by 13.23%.
The better-than-expected earnings and sales figures are likely to positively impact Syra Health's stock price in the short term. Beating both EPS and sales estimates by significant margins indicates strong operational performance and could boost investor confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100